KAZIA THERAPEUTICS LTD filed a Form D with the Securities and Exchange Commission on 2025-08-14.
KAZIA THERAPEUTICS LTD filed a Form D notice of an exempt securities offering with the SEC on August 14, 2025. The filing reports $2.05M sold. Its industry group is Biotechnology. It names John Friend (Executive Officer), Bryce Carmine (Director), Steven Coffey (Director) (SEC Form D, August 14, 2025).
Is this your company?
Sell to companies like KAZIA THERAPEUTICS LTD? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns KAZIA THERAPEUTICS LTD.
Free to see. No signup.
More on the people and the money behind KAZIA THERAPEUTICS LTD, from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when KAZIA THERAPEUTICS LTD files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when KAZIA THERAPEUTICS LTD raises, hires or launches. No email unless you switch it on.
Watch KAZIA THERAPEUTICS LTD →Get the full cited report on KAZIA THERAPEUTICS LTD
What the filing shows about KAZIA THERAPEUTICS LTD
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on KAZIA THERAPEUTICS LTD: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives KAZIA THERAPEUTICS LTD's address as Three International Towers Level 24,, 300 Barangaroo Avenue, Sydney Nsw, C3 2000.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for KAZIA THERAPEUTICS LTD →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
KAZIA THERAPEUTICS LTD is a registered filer with the SEC (CIK 1075880) and has filed since 2023-12-15. 4 filings are on record, the latest on 2025-12-18.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
KAZIA THERAPEUTICS LTD's Form D of 2025-08-14 names John Friend, Bryce Carmine, Steven Coffey and 4 more as its officers, directors or promoters.
Its new offerings report $61.36M sold across 4 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
John Friend is named as Executive Officer on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Bryce Carmine is named as Director on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Steven Coffey is named as Director on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Ebru Davidson is named as Director on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Robert Apple is named as Director on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Jeffrey Bonacorda is named as Executive Officer on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
Elissa Hansen is named as Executive Officer on the Form D that KAZIA THERAPEUTICS LTD filed with the SEC on 14 August 2025, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2025-08-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about KAZIA THERAPEUTICS LTD
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on KAZIA THERAPEUTICS LTD: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on KAZIA THERAPEUTICS LTD covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist KAZIA THERAPEUTICS LTDYou get an alert in MentionFox the next time this company shows up.
If you're behind KAZIA THERAPEUTICS LTD: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for KAZIA THERAPEUTICS LTD. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/kazia-therapeutics-ltd-form-d-25000002